-- 由於美伊和平談判前景不明朗，投資人保持謹慎，阿聯酋股市週三收跌。 收盤時，富時ADX綜合指數下跌0.764%，杜拜金融市場綜合指數下跌1.059%。 美國總統川普表示，他已延長與伊朗的停火協議，並將繼續封鎖伊朗港口，直至提交「統一方案」並完成談判。 與此同時，伊朗外長賽義德·阿巴斯·阿拉格奇在社交媒體上發文稱，封鎖伊朗港口是“戰爭行為”，違反了停火協議。阿拉格奇也表示，伊朗有能力解除這些封鎖。 「戰爭局勢依然撲朔迷離。儘管停火期限臨近，川普總統宣佈在最後一刻延長停火協議，這可能在一定程度上提振了美元兌其他貨幣對的樂觀情緒。但霍爾木茲海峽的局勢依然不明朗，美國封鎖仍在繼續，且有報道稱，一艘英國集裝箱船昨日遭到伊朗砲擊。」荷蘭國際集團（INGING）表示。 在國內企業方面，棕櫚體育（Palms Sports，ADX：PALMS）股價下跌2.69%。這家體育管理公司公佈，第一季歸屬於股東的淨利潤為1860萬阿聯酋迪拉姆，主要得益於合約擴張和有效的成本控制。 在杜拜，BHM Capital Financial Services（DFM：BHMCAPITAL）批准了2025年股東分紅總額為20%的計劃，其中包括5%的現金股利和15%的紅股。這家金融服務集團的股價收盤上漲5.51%。
Related Articles
Equities
Canada's Retail Sales Momentum May Fade Later in The Year, Says National Bank
Statistics Canada's advance estimate points to a 0.6% month-over-month nominal increase in March retail sales, said National Bank of Canada after Friday's data.Given the surge in gasoline prices that occurred in the month, this figure heavily reflects higher prices at the pump. As a result, in real terms, retail sales could register a contraction in the final month of Q1, noted the bank.Nonetheless, for the quarter, information received to date indicates that real retail sales could grow at a 4.7% annualized pace, following a 2.0% decline in the previous quarter -- marking the strongest quarterly performance since Q4 2024, stated National Bank.This is all the more impressive as it is occurring against a backdrop of demographic contraction, pointed out the bank.Indeed, the most recent figures from StatsCan indicate that the country's population declined for a second consecutive quarter -- an unprecedented development.As a result, real retail spending per capita is tracking a 5.2% increase in Q1, a rebound from the sluggish prints seen in 2025. Still, National Bank thinks that this momentum could fade fast as the year progresses.As a result of the conflict in the Middle East, households will face an erosion in purchasing power in the coming months. This, combined with a mortgage interest-payment shock and a still fragile labor market, could weigh on discretionary spending going forward, according to the bank.
$$CXY
Australia
Cinemark Likely to Benefit From Release Slate, Wedbush Says
Cinemark (CNK) is set to benefit from a more consistent release slate over the next several quarters and further market share gains, Wedbush said in a Monday note."The summer slate, especially in Q3, is shaping up very nicely," the report said.The note said theater investments, including laser projectors, premium seats and screens, IMAX expansion, and strategic pricing could drive market share gains. It also pointed to other benefits such as new builds and returning cash to shareholders.For its Q1 results due May 1, Wedbush expects Cinemark to post Q1 revenue of $638 million, against consensus of $629 million, and a loss of $0.03 per share, against consensus of $0.16 loss.Wedbush kept its outperform rating and a $37 price target.Price: $29.40, Change: $+0.92, Percent Change: +3.23%
$CNK
Asia Markets
Swiss Market Index Closes Little Changed; Santhera Shares Jump
The blue-chip Swiss Market Index was down 0.03% on Monday's close, as investors gear up for a busy week of corporate updates, economic data prints and key monetary policy decisions.Santhera Pharmaceuticals (SANN.SW) secured a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to expand the approval of its Duchenne muscular dystrophy drug Agamree to include the treatment of children who are at least two years old. The drug is currently approved for use on patients aged four and above. The Swiss specialty pharmaceutical company's shares gained 8.38% at closing.Meanwhile, RBC Capital Markets reiterated its outperform rating on Lonza Group (LONN.SW), with a price target of 670 francs, amid expectations that the Swiss pharmaceutical manufacturer's upcoming first-quarter update would be "uneventful." At the end of the trading day, the stock was up 1.83%."We do not see the Q1 qualitative update on 8 May to be a major catalyst for the stock now that Vacaville-specific commentary will no longer be provided, and any further weakness in Specialized Modalities should not be a surprise. We have also taken the opportunity to refresh and add to our commercial product (Enflonsia) and pipeline trackers. There has been some clinical progress, but consensus forecasts have been pushed out a little (aggregate peak sales estimates are unchanged)," the research firm said, noting that it views Lonza as an "attractive and undervalued compounding investment story."The local economic news calendar was empty for the day, while the release of the Swiss KOF Economic Barometer and the UBS & CFA Society Switzerland's economic sentiment index for April, as well as the country's March retail sales figures are on the agenda over the coming days. Market watchers are also awaiting the rate decisions of the US Federal Reserve, the European Central Bank, and the Bank of England.
$^SSMI$LONN.SW$SANN.SW